Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2017 - 201912020 - 20211

Settings

Author: search.filters.author.Asan, AliHas files: No

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Factors Affecting Responsiveness to Hepatitis B Immunization in Dialysis Patients
    (2017) Asan, Ali; Demirhan, Huriye; Sorkun, Hulya Cetin; Ozkan, Sevgi; Aydin, Mehtap; Akin, Davut; Tatar, Bengu; Catak, Binali; Sener, Alper; Kose, Sukran; https://orcid.org/0000-0003-4044-9366; 28620716; HLX-0937-2023
    Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are widespread health problems all over the world and have high morbidity and mortality. Hemodialysis patients are more frequently exposed to these viruses as they have poor immune system and frequently undergo parenteral interventions. The vaccination against HBV prevents infection and it has been recommended for the prevention of HBV infection in all susceptible dialysis patients. This study aimed to determine the seroprevalence of HBV and HCV infections and analyzed the factors affecting inadequate response to HBV vaccine in dialysis patients. The data for 584 dialysis patients that were followed up at seven dialysis centers were analyzed. The patients received four doses of 40 mu g recombinant hepatitis B vaccine at 0, 1, 2, and 6 months and were tested for anti-HBs titer after one month of completion of vaccination. If patients showed a titer of anti-HBs < 10 IU/mL, an additional 40 mu g in four vaccine doses was administered immediately and they were retested for the anti-HBs following the same schedule. The patients were divided into two groups: responders and non-responders. HBsAg and anti-HCV seroprevalence was 3.4% and 10.3%, respectively. After vaccination schedule, 264 (83.5%) patients had antibody response to HBV vaccine and 52 (16.5%) had no response. Hepatitis B vaccine unresponsiveness is more common in the patients with hepatitis C positivity (p = 0.011), BMI > 30 (p = 0.019), over the age of 65 years (p = 0.009), and duration of dialysis treatment > 5 years (p = 0.001). There was no statistically significant difference between gender, causes of renal disease, erythropoietin treatment, and the type of dialysis. Hepatitis C infection, obesity, being elderly, and having long hemodialysis period reduced the hepatitis B vaccination response in hemodialysis patients.
  • No Thumbnail Available
    Item
    Changes in Antimicrobial Resistance and Outcomes of Health Care-Associated Infections
    (2021) Aydin, Mehtap; Azak, Emel; Bilgin, Huseyin; Menekse, Sirin; Asan, Ali; Mert, Habibe Tulin Elmaslar Habibe Tulin Elmaslar; Yulugkural, Zerrin; Altunal, Lutfiye Nilsun; Hatipoglu, Cigdem Ataman; Ertem, Gunay Tuncer; Altunok, Elif Sargin; Demirkaya, Melike Hamiyet; Ceviker, Sevil Alkan Sevil Alkan; Akgul, Fethiye; Memis, Zeynep; Konya, Petek; Azap, Alpay; Aydin, Gule; Korkmaz, Derya; Karakoc, Zehra Cagla; Yapar, Derya; Karakecili, Faruk; Gunal, Ozgur; Keske, Siran; Kapmaz, Mahir; Kader, Cigdem; Demirel, Aslihan; Ergonul, Onder; 33586014
    To describe the change in the epidemiology of health care-associated infections (HAI), resistance and predictors of fatality we conducted a nationwide study in 24 hospitals between 2015 and 2018. The 30-day fatality rate was 22% in 2015 and increased to 25% in 2018. In BSI, a significant increasing trend was observed for Candida and Enterococcus. The highest rate of 30-day fatality was detected among the patients with pneumonia (32%). In pneumonia, Pseudomonas infections increased in 2018. Colistin resistance increased and significantly associated with 30-day fatality in Pseudomonas infections. Among S. aureus methicillin, resistance increased from 31 to 41%.